James Hodges
Internal Medicine · Waco, TXNPI 1962441600
Payments from drug & device makers
Across 145 payments — averaging $12.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$343
- Novo Nordisk$221
- Astellas Pharma US Inc$178
- Amarin Pharma, Inc.$162
- AbbVie$157
- Arbor Pharmaceuticals, Inc.$153
- plus $632 from 14 others
What the payments were for
- Food & beverage$1,847100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 42 | $343 |
| Novo Nordisk | 19 | $221 |
| Astellas Pharma US Inc | 11 | $178 |
| Amarin Pharma, Inc. | 11 | $162 |
| AbbVie | 10 | $157 |
| Arbor Pharmaceuticals, Inc. | 13 | $153 |
| Amgen | 6 | $99 |
| Kowa Pharmaceuticals America, Inc. | 6 | $92 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $90 |
| AstraZeneca | 5 | $86 |
| Pfizer | 3 | $56 |
| Johnson & Johnson | 4 | $51 |
| Radius Health, Inc. | 3 | $44 |
| Endotronix, Inc. | 1 | $26 |
| Grifols USA, LLC | 1 | $18 |
| Boehringer Ingelheim | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Merck | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
How this compares
$1,847 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 55 | $15,693 |
| JardianceEmpagliflozin | 36 | $13,195 |
| EntrestoSacubitril/Valsartan | 20 | $10,802 |
| XareltoRivaroxaban | 28 | $7,454 |
| JanuviaSitagliptin Phosphate | 25 | $7,184 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $6,831 |
| Bupropion XlBupropion Hcl | 25 | $5,069 |
| MyrbetriqMirabegron | 17 | $4,198 |
| Fluphenazine Hcl | 16 | $2,720 |
| Divalproex Sodium | 100 | $2,692 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $2,338 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 28 | $2,272 |
| Gabapentin | 158 | $2,239 |
| Atorvastatin Calcium | 200 | $1,870 |
| LantusInsulin Glargine,hum.Rec.Anlog | 19 | $1,792 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $56 | $15,69355 claims |
| Boehringer IngelheimJardiance | $16 | $13,19536 claims |
| Johnson & JohnsonXarelto | $51 | $7,45428 claims |
| MerckJanuvia | $14 | $7,18425 claims |
| Astellas Pharma US IncMyrbetriq | $178 | $4,19817 claims |
| Novo NordiskNovolog | $221 | $95312 claims |
| Lilly USA, LLCInsulin Lispro | $14 | $64019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Waco
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.